Lux Capital has announced it has closed a new $350 million fund that will invest in early-stage science and technology ventures.

Lux Capital, with offices in New York and Menlo Park, Calif., invests in counter-conventional, seed and early stage science and technology ventures. It was co-founded by Peter Hebert, Robert Paull and Josh Wolfe in 2000.

The new fund — Lux Ventures IV — brings the firm’s total capital under management to $700 million.

Among Lux Capital’s current healthcare investments include Kala Pharmaceuticals, clinical stage pharmaceutical company focused on treatments for ocular diseases; 3Scan, which develops 3D brain scans and digital organ reconstruction; and Aptible, a cloud-based platform designed to automate HIPAA compliance.